Incorporation of Lateral Microfiltration with Immunoaffinity for Enhancing the Capture Efficiency of Rare Cells

Incorporation of Lateral Microfiltration with Immunoaffinity for Enhancing the Capture Efficiency of Rare Cells

Posted by Adam Awdish on

Single Donor Human Whole Blood from Innovative Research was used in the following study:

 

Incorporation of Lateral Microfiltration with Immunoaffinity for Enhancing the Capture Efficiency of Rare Cells

Kangfu Chen, Jacob Amontree, Jose Varillas, Jinling Zhang, Thomas J. George & Z. Hugh Fan

Scientific Reports
August 26, 2020

Circulating tumor cells (CTCs) are considered to be an important biomarker for the early detection of cancer, in therapeutic monitoring, and in disease prognosis. Unfortunately, CTCs are very rare, with only a few CTCs present among the billions of normal blood cells found in each milliliter of peripheral blood, making CTCs isolation difficult.

There are currently two main methods for isolating rare cells: filtration methods based on physical properties (such as cell size) and methods based on biological properties (such as immunoaffinity). Since CTCs are generally larger than normal blood cells, filtration using microfabricated porous membranes has been employed to isolate CTCs. These microstructures can be made in different sizes, various shapes, and unique arrangements, as well as use different substrate materials, help to change the flow patterns and increase the collisions between CTCs and capture agents on microposts.

Many efforts have been made to increase CTC capture efficiency in immunoaffinity-based methods. One effective approach has been to enhance the interaction between CTCs and the antibodies immobilized in devices. While this provides more opportunities for CTCs and antibodies to interact, it does not prevent the cloaking effect, which is when a CTC is loosely surrounded by platelets and other blood cells, which can reduce the direct contact opportunities between the CTC and antibodies immobilized in the filtration device.

This study tested a new filtration device which combines size-based microfiltration into a microfluidic device with immunoaffinity for enhanced capture efficiency of CTCs. The device design is optimized to make all fluid particles interact with filters, which range in size from 24 to 12 µm, being slightly larger than or having similar dimension of CTCs. These filters are immobilized with antibodies specific to CTCs and thus they function as gates, allowing normal blood cells to pass by while forcing the interactions between CTCs and antibodies on the filter surfaces.

 

Related products available from Innovative Research also include:

Single Donor Human Red Blood Cells Washed

Single Donor Human Plasma (Blood Derived)

Pooled Human Serum Off The Clot

  • Tags: Human Blood Cells, Human Whole Blood

    • The next big thing: it's what you do. The biological research materials you need to discover it? That's what we do! We love seeing how our products are being used in real-life applications and contributing to scientific acheivements every day. With thousands of published references and decades of proven results, you can count on us to help you source the high-quality biomaterials you need that will deliver reliable, consistent results - kit to kit, lot to lot, all study long. So what are you waiting for? All great discoveries start somewhere... yours starts with Innovative Research! Get in touch with our team today!


    Related Posts

    Plasma MMP-3: A Novel Biomarker Predicting ARDS Patient Outcomes
    In the quest to enhance patient care in critical conditions, the discovery of predictiv...
    Read the Article
    Top 5 Biologicals to Buy Right Now
    Innovative Research is excited to share our top 5 biological products that are making w...
    Read the Article
    Innovative Research’s Role in Developing a Zero-Gravity Versatile Sample Preparation Platform (VSPP)
    The realm of space exploration continually seeks innovations that can enhance the safet...
    Read the Article

    ← Older Post Newer Post →

    ×